AI, licensing and remote prescribing among key issues facing telepsychiatry

The U.S. Drug Enforcement Administration's position on telehealth prescriptions has been changing, with indications that the agency may be interested in long-term flexibility. This, along with other policy changes, directly affects healthcare provider organisations and businesses who provide care virtually through telemedicine. In addition, telepsychiatry continues to advance in the post-public health emergency environment. Beyond remote prescribing, there are numerous difficulties to be mindful of in this situation, which call for forethought and originality on the part of provider organisations and virtual care companies.

Geoffrey Boyce, CEO and cofounder of Array Behavioral Care, a telemedicine company that specializes in behavioral health, spoke with Healthcare IT News about the DEA, the difficulties of telepsychiatry, and much more.